After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association

In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH diagnosis between January 2013 and December 2021 from the TriNetX database to determine how GLP-1 receptor agonist use (n = 1,714) impacts all-cause mortality, respiratory failure, atrial fibrillation, right heart failure and ED visits vs
During acute diverticulitis with persistent vomiting or inability to maintain fluids, follow sick day rules and temporarily withhold the medication, but seek medical advice promptly
Rarely, rashes or skin reactions have been reported
The surgical team has cleared progression to active range-of-motion exercises